A controlled study comparing visual function in patients treated with vigabatrin and tiagabine

G L Krauss, M A Johnson, S Sheth, N R Miller

Objective: Vigabatrin treatment is frequently associated with irreversible retinal injury and produces retinal electrophysiological changes in nearly all patients. Concern has been raised that tiagabine and other antiepilepsy drugs (AEDs) that increase γ-aminobutyric acid (GABA) might produce similar electrophysiological and clinical changes in visual function. The study compared visual function between groups of patients with epilepsy treated long term with tiagabine, vigabatrin, and patients treated with other AEDs.

Methods: A cross sectional study comparing visual acuity, colour vision, static and kinetic perimetry, and electroretinograms between groups of patients treated with tiagabine, vigabatrin, and other AEDs (control patients). Patients were adults receiving stable AED treatment for >6 months.

Results: Vigabatrin treated patients had marked visual field constrictions in kinetic perimetry (mean radius 39.6° OD, 40.5° OS); while tiagabine patients had normal findings (mean 61° OD, 62° OS) [differences OD and OS, p=0.001], which were similar to epilepsy control patients (mean 60° OD, 61° OS). Vigabatrin patients had abnormal electroretinographic photopic B wave, oscillatory, and flicker responses, which correlated with visual field constrictions. These electroretinographic responses were normal for tiagabine patients and control patients. Patients were treated with vigabatrin for a median of 46 months compared with 29 months for tiagabine. Patients taking other AEDs that may change brain GABA had normal visual function.

Conclusion: Unlike vigabatrin, tiagabine treatment is associated with normal electroretinography and visual fields and ophthalmological function similar to epilepsy control patients. Differences between vigabatrin and other GABA modulating AEDs in retinal drug concentrations and other effects might explain why tiagabine increases in GABA reuptake do not cause retinal injury.

Vigabatrin is associated with concentric visual field deficits in about 40% of treated patients. These defects appear to develop between three months and three years after the start of vigabatrin treatment and tend to persist despite cessation of the drug.1-3 The results of electrophysiological testing indicate that the major cause of the visual loss in patients taking vigabatrin is damage to the inner retina.4,5 Vigabatrin raises the concentration of γ-aminobutyric acid (GABA) in the brain by irreversibly blocking GABA transaminase,6 and it is believed that the retinal dysfunction that occurs in patients taking vigabatrin is related to a similar effect in the eye. Tiagabine blocks reuptake of glial and neuronal GABA.7,8 The concern has therefore been raised that tiagabine and other antiepilepsy drugs (AEDs) that augment GABA neurotransmission might also produce visual deficits from their effects on the retina.

In a preliminary report, Beran et al reported that 6 of 12 patients treated with tiagabine developed visual field defects.9 More recently, Kaufman reported a similar case.10 Nousiainen, however, reported no visual field defects in 15 patients treated with tiagabine monotherapy.11 These conflicting findings may be attributable to methodological problems12; however, they raise the possibility that tiagabine might produce visual dysfunction.13

We performed a cross sectional, controlled study to determine if tiagabine causes electrophysiological and clinical changes in visual function similar to those associated with vigabatrin. We compared several measures of ophthalmological function—visual acuity, colour vision, fundoscopic examination, visual fields using both static (Humphrey) and kinetic (Goldmann) perimetry, and electroretinography (ERG)—in patients treated with tiagabine, and in control patients with epilepsy taking other AEDs. These data were compared with patients treated with vigabatrin evaluated previously in an identical fashion.

METHODS

Patients and inclusion criteria

Patients were adult volunteers with epilepsy (12 tiagabine, 32 vigabatrin, and 14 control patients) recruited from the Johns Hopkins University epilepsy clinic and from other clinics in the US mid-Atlantic states (Maryland, Pennsylvania, New Jersey, Virginia, West Virginia, Delaware). Patients were excluded if they had pre-existing serious ocular disorders. Patients with previous exposure to vigabatrin were not included in the tiagabine and control study groups. Study consent was obtained for all participants using a consent approved by the Johns Hopkins University Joint Committee on Clinical Investigation.

Study patients had received treatment with tiagabine or vigabatrin for a minimum of six months at a stable dose and were permitted to take concomitant AEDs. The control patients had epilepsy and were group matched to tiagabine patients by age range, range of seizure frequency, and concomitant AEDs. Investigators performing the ophthalmological testing were blinded both to treatment conditions and to medical history. Control and tiagabine patients were tested in a randomised sequence. Vigabatrin patients were studied in a separate controlled study under identical conditions. Vigabatrin study results, but not vigabatrin and tiagabine comparisons, were previously published.14

Abbreviations: GABA, γ-aminobutyric acid; AED, antiepilepsy drug; ERG, electroretinography; KVF, kinetic visual field
Ophthalmology testing
Every patient underwent a complete neuro-ophthalmological evaluation by a physician and a technician, both of whom were unaware of the patient’s clinical status and medications. The evaluation included testing of visual acuity using a projected wall chart, pinhole visual acuity, colour vision using Hardy-Rand-Rittler (HRR) pseudoisochromatic plates, and visual field testing. Visual field testing was performed by kinetic perimetry using a Goldmann manual perimeter and by static perimetry using the 24–2 strategy on a Humphrey automated perimeter. During kinetic perimetry, fixation was carefully monitored by direct visualisation of the fixing eye, and catch trials (rechecking points both outside and within the area of apparently seeing field at specific meridia) were performed. During automated static perimetry, the foveal threshold was on, and reliability indices were automatically assessed. We subsequently excluded visual field results for one vigabatrin patient with mental retardation whose responses during testing were unreliable during both kinetic and static perimetry; however, her ERG results are included in our analysis.

ERG b-wave amplitudes were measured as the difference in µV between the trough of the a-wave and the peak of the b-wave. ERG data were evaluated by comparison with a population of 100 normal subjects aged 20–80 years previously evaluated at Johns Hopkins and the University of Wisconsin, Madison. For all ERG signals, the best linear relation between an age and parameter was determined and an equation was derived that described this relation.Individual subjects were considered to be abnormal if their data fell below two standard deviations of the age matched mean determined in this way. ERG amplitude and timing were also compared between vigabatrin treated patients and tiagabine and control patients using Student’s t tests. Analysis of visual field data was performed by several methods. For kinetic perimetry, we used the V/4e test object and then determined the mean peripheral field diameter by measuring the radial distance of the intact field in degrees from fixation at each of 12 points, 30° apart. We then averaged the results for each eye of each patient. We also averaged the results for the nasal and temporal homonymous hemifields separately. All results were compared with those obtained from the control patients. For static perimetry, we assessed the mean deviation for each eye and compared the results with those obtained from the control subjects. We also compared the performance of both patients and controls with respect to the reliability indices.

RESULTS
Patient characteristics
A total of 12 tiagabine patients, 32 vigabatrin patients, and 14 control patients were assessed. Age, sex, seizure frequency, and number of prior AEDs were similar among the treatment groups (Table 1). Concomitant AEDs were similar except that none of the vigabatrin patients was taking levetiracetam, and none of the tiagabine patients was taking valproic acid or lamotrigine. The median duration of vigabatrin therapy was 46.5 months compared with 29 months for tiagabine treatment.

Ophthalmological examination
Acuity
There were no differences in acuity between tiagabine and control patients (OD, p=0.687; OS, p=0.202). Three vigabatrin patients (9%) had best corrected acuity of 20/20 or worse OD, whereas no tiagabine patients or control patients had acuity worse than 20/20 OD. One tiagabine patient and one vigabatrin patient had 20/40 or worse acuity OS. However, there were no significant differences in acuity between tiagabine and vigabatrin patients (OD, p=0.185; OS, p=0.823).

Table 1 Clinical characteristics of patient population

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Vigabatrin patients</th>
<th>Tiagabine patients</th>
<th>Control patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female</td>
<td>20/12</td>
<td>8/4</td>
<td>7/7</td>
</tr>
<tr>
<td>Age, mean years (range)</td>
<td>43.1 (22–73)</td>
<td>42.2 (26–70)</td>
<td>40 (21–71)</td>
</tr>
<tr>
<td>Duration of treatment, months (range)</td>
<td>46.5 (27–78) vigabatrin</td>
<td>29 (7–60) tiagabine</td>
<td>0</td>
</tr>
<tr>
<td>Median monthly seizure frequency, (range)</td>
<td>3.6 (0–31)</td>
<td>4.0 (1–30)</td>
<td>3 (0–30)</td>
</tr>
<tr>
<td>Median number of prior AEDs, (range)</td>
<td>6 (3–11)</td>
<td>3 (2–4)</td>
<td>3 (2–8)</td>
</tr>
<tr>
<td>Number of patients taking concomitant AEDs</td>
<td>19</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>carbamazepine</td>
<td>4</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>phenytoin</td>
<td>9</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>gabapentin</td>
<td>4</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>lamotrigine</td>
<td>5</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>phenobarbital</td>
<td>0</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>primidone</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>topiramate</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>valproic acid</td>
<td>4</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>levetiracetam</td>
<td>0</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Aetiology of seizures</td>
<td>idiopathic</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>symptomatic</td>
<td>16</td>
<td>4</td>
<td>7</td>
</tr>
</tbody>
</table>

Table 2 Results of visual field testing in tiagabine, vigabatrin, and control patients

<table>
<thead>
<tr>
<th>Technique</th>
<th>Tiagabine patients</th>
<th>Vigabatrin patients</th>
<th>Control patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=12</td>
<td>n=32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kinetic OD</td>
<td>−1.98 dB</td>
<td>−1.98 dB</td>
<td>−0.54 dB</td>
</tr>
<tr>
<td>Kinetic OS</td>
<td>−1.98 dB</td>
<td>−1.98 dB</td>
<td>−0.54 dB</td>
</tr>
<tr>
<td>Static OD</td>
<td>−1.67 dB</td>
<td>−1.67 dB</td>
<td>−0.54 dB</td>
</tr>
<tr>
<td>Static OS</td>
<td>−1.67 dB</td>
<td>−1.67 dB</td>
<td>−0.54 dB</td>
</tr>
</tbody>
</table>

*Obtained by unpaired t test. †No significant difference compared with tiagabine patients.
Colour
There were no differences in colour vision between tiagabine and control patients (OD, p=0.455; OS, p=0.144). One patient treated with tiagabine had slightly reduced (8/10) colour vision compared with normal values for control patients. Four vigabatrin patients (9%) had abnormal colour vision (<8/10).

Visual fields
Kinetic visual fields (Goldmann perimetry)
Vigabatrin patients had markedly constricted kinetic visual fields compared with tiagabine patients (vigabatrin treatment, mean radius 39.6° OD, 40.5° OS; tiagabine patients, mean 61° OD, 62° OS; both p<0.001) (table 2 and fig 1). Mean kinetic visual fields were nearly identical between tiagabine patients and control patients (mean 60° OD, 61° OS) (table 2 and fig 1).

Static visual fields (Humphrey perimeter)
Vigabatrin patients had slightly greater static visual field mean deviations than tiagabine patients or control patients (vigabatrin −4.7 dB OD, −4.7 dB OS); however, this did not reach statistical significance (table 2). Seven patients treated with vigabatrin, however, and no tiagabine or control patients had very high mean deviations (>8). Mean static visual fields were normal for both tiagabine patients (−1.9 dB OD, −1.8 dB OS) and control patients (−0.54 dB OD, −0.54 dB OS) (table 2). One control patient and one tiagabine patient had slightly reduced kinetic and static visual fields on initial testing, but normal values on retesting. Overall, the controls and tiagabine patients had excellent reliability indices whereas the vigabatrin treated patients tended to have abnormal reliability indices that mirrored their visual field deficits.

Fundoscopy
All tiagabine patients had normal fundi as did all control patients. Among the vigabatrin patients, 23 (71.9%) had abnormalities in the ocular fundi, including retinal arterial narrowing, epiretinal membrane formation, an irregular sheen or abnormal pigment in the macula, and reduction in the peripapillary nerve fibre layer. Two vigabatrin patients had pale optic discs.

Electroretinogram findings
Cone system
Vigabatrin patients had marked reductions in ERG photopic b-wave, flicker and oscillatory responses compared with patients treated with tiagabine, control patients, and with age matched laboratory norms (OD and OS, both p<0.001) (table 3 and figs 2 and 3). Photopic b-wave, flicker responses and oscillatory responses were nearly identical for tiagabine patients and control patients (table 3 and fig 2).

Rod system
Vigabatrin patients had significantly diminished rod b-wave amplitudes (mean (SD) 103.1 (42) µV OD, 96.5 (41.7) µV OS) compared with tiagabine patients (140.92 (42) µV OD; 139.75 (44) µV OS; difference OD, p=0.001; OS p=0.004), though the magnitude of these differences was smaller than for cone system driven responses. Rod b-wave amplitude for tiagabine patients were similar to control patients (151 (44) µV OD, p=0.6; 151 (41) µV OS, p=0.5).

Visual field and ERG correlations
KVF and photopic b wave amplitudes strongly correlated for vigabatrin treated patients, but not for tiagabine and control patients (fig 3). No significant correlations were shown between kinetic visual fields (KVF) and photopic b wave amplitudes, KVF and rod b-wave amplitudes, or SVF and photopic b wave amplitudes for tiagabine patients.

Other AEDs affecting GABA
Eight patients in the epilepsy control and tiagabine groups were chronically treated with other AEDs that have been

<table>
<thead>
<tr>
<th>Technique</th>
<th>Tiagabine patients n=12</th>
<th>Vigabatrin patients n=32</th>
<th>t Statistics</th>
<th>p Value*</th>
<th>Control patients† n=14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Photopic OD</td>
<td>89.5</td>
<td>48.4</td>
<td>5.3478</td>
<td>&lt;0.001</td>
<td>84.7</td>
</tr>
<tr>
<td>Photopic OS</td>
<td>88.5</td>
<td>48.5</td>
<td>6.4162</td>
<td>&lt;0.001</td>
<td>88.8</td>
</tr>
<tr>
<td>Flicker OD</td>
<td>68.6</td>
<td>31.9</td>
<td>6.3903</td>
<td>&lt;0.001</td>
<td>69.4</td>
</tr>
<tr>
<td>Flicker OS</td>
<td>74.4</td>
<td>31.2</td>
<td>9.7805</td>
<td>&lt;0.001</td>
<td>72.1</td>
</tr>
<tr>
<td>Oscillatory OD</td>
<td>113.8</td>
<td>55.5</td>
<td>4.014</td>
<td>0.0002</td>
<td>137.5</td>
</tr>
<tr>
<td>Oscillatory OS</td>
<td>128.2</td>
<td>47.3</td>
<td>6.0772</td>
<td>&lt;0.001</td>
<td>136.8</td>
</tr>
</tbody>
</table>

*Obtained by unpaired t test. †No significant difference compared with tiagabine patients.
showed to modulate brain GABA: gabapentin, topiramate, valproic acid. These patients had normal visual findings, including normal KVF (mean 61.1 OD; 61.4 OS) and ERG flicker (mean 70.7 OD; 74.5 OS), testing that was abnormal in vigabatrin patients.

**DISCUSSION**

All vigabatrin treated patients had ERG abnormalities (decreased photopic b-wave, flicker or oscillatory potential amplitudes), and 53% had visual field constrictions on KVF. Visual function testing for tiagabine treated patients, however, was similar to control patients with epilepsy. This is evidence that tiagabine is dissimilar to vigabatrin and does not produce clinically significant alteration in retinal function after intermediate periods of exposure (six months to five years).

The median exposure for patients treated with vigabatrin in our study was longer (46 months) than for tiagabine patients (29 months), however, vigabatrin patients treated for similar periods (one half of the total) had markedly abnormal ERG and visual fields similar to patients treated for longer periods. Only a small number of patients were treated with tiagabine for long periods (up to five years), however, our study shows there is no visual toxicity following intermediate periods (>6 months) of exposure. We also found that KVF was more sensitive for detecting vigabatrin related peripheral field constrictions than SVF measured with 24-2 Humphrey perimetry. We did not, however, use the more sensitive 30-2 Humphrey protocol to measure static visual fields. Even though group differences in mean deviations for SVF did not reach statistical significance, many vigabatrin treated patients had low mean deviations in SVF, thus demonstrating a loss of visual sensitivity across central retinæ in addition to their peripheral field constrictions demonstrated with KVF. Another limitation of our study was that vigabatrin patients were tested during a previous controlled study, however, test procedures were identical. Tiagabine and control patients were tested with investigators blinded to their treatment and no correlation between ERG and visual field measurements, it is unlikely that tiagabine has physiological effects similar to vigabatrin in retina.

Our findings are consistent with studies showing different mechanisms of action and distributions for vigabatrin and tiagabine. Tiagabine reduces uptake of GABA in glia and neurons, whereas vigabatrin decreases activity of GABA-transaminase and blocks GABA metabolism in neurons and astrocytes. Unlike tiagabine, vigabatrin markedly increases GABA concentrations in cortical astrocyte cultures. GABA levels in human brain are increased during vigabatrin treatment, whereas only small and variable changes are observed during tiagabine treatment. These differences in CNS effects extend to retina: vigabatrin concentrations in retina of rodents are increased fivefold compared with brain, while tiagabine concentrations are slightly decreased in retina compared with brain.

Other AEDs shown to change brain GABA concentrations in addition to tiagabine—gabapentin, topiramate, and valproic acid—also did not change visual function. This is evidence against a drug class effect for GABA-ergic anticonvulsants producing retinal toxicity, though this does not exclude the possibility that vigabatrin produces retinal injury due to GABA alterations in retinas. Physiologically activated GABA receptors in isolated retina, for example, can produce increases in extracellular Cl\textsuperscript-- and rapidly trigger excitotoxic cell death.

Patients with visual field constrictions associated with vigabatrin treatment are often unaware of their deficits until and unless they become very severe. Such patients may have difficulties with navigation or visual adaptation, however, underscoring the importance of determining if drugs that affect the central nervous system produce retinal toxicity. Although our study is too small to determine whether rare patients develop visual complications during prolonged tiagabine treatment, our patients treated with tiagabine had retinal function similar to that of non-exposed patients with epilepsy. Moreover, vigabatrin caused retinal electrophysiological changes in all patients treated, with deficits in visual function occurring in a large proportion of exposed individuals. We found no evidence for similar disturbance in tiagabine patients, suggesting vigabatrin retinal toxicity is attributable to a comparatively specific effect on retinas.

**Authors’ affiliations**

G L Krauss, S Sheth, N R Miller, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, USA

N R Miller, Department of Ophthalmology, Johns Hopkins University School of Medicine

N A Johnson, Department of Ophthalmology, University of Maryland School of Medicine

Competing interests: GLK and MAJ served as consultants to Cephalon Corporation one year ago, current manufacturer of tiagabine, and reviewed the study findings with them. The study was funded by Abbott Labs, former manufacturer.

**REFERENCES**


Visual function in patients treated with vigabatrin and tiagabine


13 Stefan H, Bernatik J, Knorr J. Visual field due to antiepileptic drugs. [In German]. Nervenarzt 1999; 70: 552–5.

NEUROLOGICAL STAMP

Allvar Gullstrand (1862–1930)

Gullstrand studied medicine at the University of Uppsala, graduated in 1887, and in 1894 became professor of ophthalmology. From his student days his career was devoted to the study of “dioptrics”, that is, the study of the human eye as a transparent system of lenses for the collection and refraction of light. He invented a number of ophthalmological instruments. Among his contributions were the correction of astigmatism using cylindrical lenses, the localisation of paralysed ocular muscles, and in 1889 he invented a photographic technique for measuring the degree of corneal astigmatism. In 1911 Gullstrand expanded Hermann von Helmholtz’s theory on the structure of the lens in accommodation. His most important technical achievement was in 1910, with the improvement of the ophthalmoscope, which had been invented by Helmholtz in 1851. This improvement was the precursor to the slit lamp Gullstrand invented in 1911. In that same year he received the Nobel prize for physiology and medicine. Gullstrand died in Uppsala in 1930. Sweden honoured him philatelically in 1971 as a Nobel laureate (Stanley Gibbons no 671, Scott no 1910). He is shown with Wilhelm Wien, who received the Nobel prize for physics in the same year.

L F Haas